New hope for kids with Crohn's: drug shows promise in small trial
NCT ID NCT01580670
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called TA-650 (also known as infliximab) in 14 children with moderate to severe Crohn's disease. The drug was given as an IV infusion to reduce inflammation and control symptoms. The goal was to see if it could lower disease activity scores and improve the children's health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TA-650 (infliximab), a drug that blocks inflammation
- What this could lead to
- If successful, this could provide a treatment option to control symptoms and improve quality of life for children with Crohn's disease.
- What could go wrong
- This is a small, completed Phase 3 trial with only 14 participants, so results may not apply to all children. Infliximab can have serious side effects like infections or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational site
Chūbu, Japan
-
Investigational site
Hokkaido, Japan
-
Investigational site
Hokuriku, Japan
-
Investigational site
Kanto, Japan
-
Investigational site
Kinki, Japan
-
Investigational site
Kyusyu, Japan
-
Investigational site
Tōhoku, Japan